Docoh
Loading...

JNJ Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Company profile

Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
IRS number
221024240

JNJ stock data

(
)

Calendar

28 Jul 21
4 Aug 21
2 Jan 22
Quarter (USD)
Jul 21 Apr 21 Jan 21 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Jul 21 Johnson & Johnson Common Stock Conversion Aquire C Yes No 0 3,495,575 0 3,495,575
2 Jul 21 Johnson & Johnson Series G Preferred Stock Common Stock Conversion Dispose C Yes No 0 48,068,690 0 0
2 Jul 21 Johnson & Johnson Series F-2 Preferred Stock Common Stock Conversion Dispose C Yes No 0 7,587,828 0 0
2 Jul 21 Johnson & Johnson Series E-2 Preferred Stock Common Stock Conversion Dispose C Yes No 0 6,451,188 0 0
2 Jul 21 Johnson & Johnson Series D-2 Preferred Stock Common Stock Conversion Dispose C Yes No 0 4,032,259 0 0
8 Jun 21 Weinberger Mark A Deferred Share Units Common Stock Grant Aquire A No No 165.46 226.087 37.41K 3,648.695
8 Jun 21 Washington A. Eugene Deferred Share Units Common Stock Grant Aquire A No No 165.46 338.567 56.02K 24,885.06
8 Jun 21 Marillyn A Hewson Deferred Share Units Common Stock Grant Aquire A No No 165.46 203.239 33.63K 3,625.847

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

66.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 3201 3172 +0.9%
Opened positions 155 375 -58.7%
Closed positions 126 116 +8.6%
Increased positions 1579 1416 +11.5%
Reduced positions 1177 1118 +5.3%
13F shares
Current Prev Q Change
Total value 287.21B 282.28B +1.7%
Total shares 1.75B 1.79B -2.5%
Total puts 12.97M 15.16M -14.5%
Total calls 15.85M 15.76M +0.6%
Total put/call ratio 0.8 1.0 -14.9%
Largest owners
Shares Value Change
Vanguard 229.73M $37.76B +0.8%
BLK Blackrock 189.69M $31.18B +0.6%
STT State Street 140.27M $23.05B -2.6%
Geode Capital Management 40.83M $6.69B +1.8%
State Farm Mutual Automobile Insurance 34.57M $5.68B 0.0%
Wellington Management 33.89M $5.57B -4.3%
BAC Bank Of America 33.22M $5.46B +1.4%
NTRS Northern Trust 32.06M $5.27B -2.0%
BK Bank Of New York Mellon 31.84M $5.23B -0.4%
Massachusetts Financial Services 27.86M $4.58B -1.4%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -27.77M EXIT
Capital World Investors 11.92M -11.48M -49.1%
STT State Street 140.27M -3.72M -2.6%
Arrowstreet Capital, Limited Partnership 9M +2.69M +42.6%
Two Sigma Advisers 2.69M +2.47M +1125.7%
Aperio 0 -2.38M EXIT
GS Goldman Sachs 12.86M +2.33M +22.1%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 5.36M +1.93M +56.2%
TROW T. Rowe Price 15.36M -1.87M -10.9%
Sanders Capital 8.44M +1.85M +28.1%

Financial report summary

?
Risks
  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • The Company faces significant regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
  • Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
  • EXECUTIVE OFFICERS OF THE REGISTRANT
  • Issuer Purchases of Equity Securities
  • Organization and Business Segments
  • Income Before Tax by Segment
  • Financing and Market Risk
  • New Accounting Pronouncements
  • Economic and Market Factors
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: admitted, aerosol, Allergy, barred, benzene, cancelled, contest, defect, discretion, driver, eCommerce, hydration, incidence, infection, insufficient, Israeli, lapping, master, MOTRIN, Nassau, onset, ORSL, preemption, professional, resume, similarly, strict, Suffolk, sunscreen, supplanted, surge, unique, unspecified, waiver, warn, wide
Removed: abiraterone, acetate, anterior, approach, Biosurgery, Cadila, Consent, Decree, establishment, globally, invalidate, Latin, leading, Minister, negatively, negligible, prohibiting, Submission, therapy, TYLENOL